CU24287B1 - Suministro de fármaco biodegradable para las composiciones hidrofóbicas - Google Patents

Suministro de fármaco biodegradable para las composiciones hidrofóbicas

Info

Publication number
CU24287B1
CU24287B1 CUP2014000148A CU20140148A CU24287B1 CU 24287 B1 CU24287 B1 CU 24287B1 CU P2014000148 A CUP2014000148 A CU P2014000148A CU 20140148 A CU20140148 A CU 20140148A CU 24287 B1 CU24287 B1 CU 24287B1
Authority
CU
Cuba
Prior art keywords
biodegradable drug
supply
hydrophobic compositions
polyester
polyethylene glycol
Prior art date
Application number
CUP2014000148A
Other languages
English (en)
Spanish (es)
Other versions
CU20140148A7 (es
Inventor
Georges Gaudriault
Christophe Roberge
Original Assignee
Medincell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49117888&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU24287(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medincell filed Critical Medincell
Publication of CU20140148A7 publication Critical patent/CU20140148A7/es
Publication of CU24287B1 publication Critical patent/CU24287B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CUP2014000148A 2012-06-27 2013-06-27 Suministro de fármaco biodegradable para las composiciones hidrofóbicas CU24287B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261665192P 2012-06-27 2012-06-27
PCT/IB2013/001547 WO2014001904A1 (fr) 2012-06-27 2013-06-27 Administration de médicament biodégradable pour compositions hydrophobes

Publications (2)

Publication Number Publication Date
CU20140148A7 CU20140148A7 (es) 2015-03-30
CU24287B1 true CU24287B1 (es) 2017-12-08

Family

ID=49117888

Family Applications (1)

Application Number Title Priority Date Filing Date
CUP2014000148A CU24287B1 (es) 2012-06-27 2013-06-27 Suministro de fármaco biodegradable para las composiciones hidrofóbicas

Country Status (24)

Country Link
US (5) US20150150987A1 (fr)
EP (1) EP2866837B1 (fr)
JP (1) JP6134788B2 (fr)
KR (1) KR102189442B1 (fr)
CN (1) CN104582733B (fr)
AU (1) AU2013282891B2 (fr)
BR (1) BR112014031773B1 (fr)
CA (1) CA2877083C (fr)
CL (1) CL2014003531A1 (fr)
CO (1) CO7160098A2 (fr)
CR (1) CR20140581A (fr)
CU (1) CU24287B1 (fr)
EA (1) EA031522B1 (fr)
ES (1) ES2938586T3 (fr)
HK (1) HK1208374A1 (fr)
IL (1) IL236472B (fr)
IN (1) IN2014DN11063A (fr)
MA (1) MA37809B1 (fr)
MX (1) MX353280B (fr)
SG (1) SG11201408658PA (fr)
TN (1) TN2014000520A1 (fr)
UA (1) UA113549C2 (fr)
WO (2) WO2014001904A1 (fr)
ZA (1) ZA201409291B (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
PT2782584T (pt) 2011-11-23 2021-09-02 Therapeuticsmd Inc Preparações e terapias de substituição para hormonoterapias naturais combinadas
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
UA119324C2 (uk) * 2013-04-02 2019-06-10 Теміс Медікер Лімітед Композиції фармацевтично активних речовин, що містять моноетиловий ефір діетиленгліколю або інші алкільні похідні
WO2015023675A2 (fr) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Comprimé extrudé anti-abus à libération immédiate
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
CA2938019A1 (fr) 2014-01-27 2015-07-30 Medincell Analogues retro-inverso de spadine a effets antidepresseurs accrus
AR100562A1 (es) 2014-05-22 2016-10-12 Therapeuticsmd Inc Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
AU2015290098B2 (en) 2014-07-17 2018-11-01 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
CN107072948A (zh) * 2014-09-30 2017-08-18 田纳西大学研究基金会 用于长效药物传递的原位凝胶剂
EP3209282A4 (fr) 2014-10-20 2018-05-23 Pharmaceutical Manufacturing Research Services, Inc. Forme galénique anti-abus de remplissage de liquide à libération prolongée
FR3027522B1 (fr) 2014-10-27 2016-12-09 I Ceram Composition poreuse chargee en principe actif
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
PT3377041T (pt) * 2015-11-16 2023-12-15 Maria Pereira Da Cruz Alves Garcia Método para morcelação e/ou direcionamento de princípios farmaceuticamente ativos ao tecido sinovial
BR112018070199A2 (pt) 2016-04-01 2019-01-29 Therapeuticsmd Inc composição farmacêutica de hormônio esteroide
WO2017173044A1 (fr) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Compositions d'hormones stéroïdes dans des huiles à chaîne moyenne
WO2018081138A1 (fr) * 2016-10-24 2018-05-03 Yale University Implants contraceptifs biodégradables
JP2020511483A (ja) 2017-03-20 2020-04-16 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ 徐放性オランザピン製剤
WO2019016233A1 (fr) * 2017-07-17 2019-01-24 Medincell Composition pharmaceutique
CN108078911A (zh) * 2017-12-08 2018-05-29 复旦大学 用于动物避孕的热致水凝胶缓释兽药注射剂及其制备方法
WO2020041378A1 (fr) * 2018-08-22 2020-02-27 Bacainn Therapeutics, Inc. Compositions de cyclosporine et méthodes d'utilisation
GB201900258D0 (en) * 2019-01-08 2019-02-27 Medincell Pharmaceutical composition
CN114727946A (zh) * 2019-09-13 2022-07-08 美蒂森股份公司 药物递送制剂
CN111700876A (zh) * 2020-03-12 2020-09-25 上海市肿瘤研究所 一种治疗系统性红斑狼疮的载药递送给药系统及其制备方法
WO2022129417A1 (fr) 2020-12-16 2022-06-23 Medincell Méthodes et compositions pour le traitement prophylactique du virus sars-cov-2 (covid-19)
FI20215186A1 (en) 2021-02-19 2022-08-20 Rebio Tech Oy Compositions for ophthalmic treatment
MX2023010925A (es) 2021-03-17 2023-09-27 Medincell S A Formulacion inyectable de accion prolongada que comprende risperidona y polimeros biodegradables.
AU2022264844A1 (en) * 2021-04-30 2023-11-23 Medincell Sa New formulation

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8416234D0 (en) * 1984-06-26 1984-08-01 Ici Plc Biodegradable amphipathic copolymers
HU222501B1 (hu) * 1991-06-28 2003-07-28 Endorecherche Inc. MPA-t vagy MGA-t tartalmazó nyújtott hatóanyag-felszabadulású gyógyászati készítmény és eljárás előállítására
US5518730A (en) * 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
KR0180334B1 (ko) * 1995-09-21 1999-03-20 김윤 블럭 공중합체 미셀을 이용한 약물전달체 및 이에 약물을 봉입하는 방법
FR2741628B1 (fr) 1995-11-29 1998-02-06 Centre Nat Rech Scient Nouveaux hydrogels a base de copolymeres trisequences et leur application notamment a la liberation progressive de principes actifs
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
AU2002214466A1 (en) * 2000-11-09 2002-05-21 Astrazeneca Ab Oral pharmaceutical composition containing a block copolymer
KR100446101B1 (ko) * 2000-12-07 2004-08-30 주식회사 삼양사 수난용성 약물의 서방성 제형 조성물
EP1392254B1 (fr) 2001-04-20 2007-06-06 The University of British Columbia Systemes d'administration de medicament micellaire pour medicaments hydrophobes
US6592899B2 (en) 2001-10-03 2003-07-15 Macromed Incorporated PLA/PLGA oligomers combined with block copolymers for enhancing solubility of a drug in water
US7649023B2 (en) * 2002-06-11 2010-01-19 Novartis Ag Biodegradable block copolymeric compositions for drug delivery
JP2009513493A (ja) * 2003-06-26 2009-04-02 メディオラニューム ファーマシューティカルス リミテッド 制限された活性成分の初期放出を有し、続いてその徐放性を直線的に変化させる皮下インプラント
US20050112170A1 (en) * 2003-11-20 2005-05-26 Hossainy Syed F. Coatings for implantable devices comprising polymers of lactic acid and methods for fabricating the same
WO2007019439A2 (fr) * 2005-08-04 2007-02-15 Angiotech International Ag Compositions de copolymere sequence et utilisations de ces dernieres
CN101273963A (zh) * 2007-11-22 2008-10-01 山东蓝金生物工程有限公司 一种含激素类抗癌药的温控缓释注射剂
US8846068B2 (en) * 2008-04-18 2014-09-30 Warsaw Orthopedic, Inc. Methods and compositions for treating post-operative pain comprising a local anesthetic
CN102292109A (zh) * 2008-11-21 2011-12-21 株式会社三奍社 用于治疗耐受性癌症的聚合物胶束组合物及其制备方法
CN101810560B (zh) * 2009-02-20 2013-07-10 北京大学 环孢a聚合物胶束组合物
BR112013016662B1 (pt) * 2010-12-29 2021-08-03 Medincell Composições biodegradáveis para administração de fármaco

Also Published As

Publication number Publication date
EP2866837A1 (fr) 2015-05-06
WO2014001905A1 (fr) 2014-01-03
IL236472A0 (en) 2015-02-26
KR20150027265A (ko) 2015-03-11
CO7160098A2 (es) 2015-01-15
TN2014000520A1 (en) 2016-03-30
KR102189442B1 (ko) 2020-12-11
MA37809B1 (fr) 2018-12-31
CA2877083A1 (fr) 2014-01-02
US20210008216A1 (en) 2021-01-14
BR112014031773B1 (pt) 2020-10-13
IL236472B (en) 2020-02-27
AU2013282891A2 (en) 2015-02-05
EA201492172A1 (ru) 2015-09-30
WO2014001904A1 (fr) 2014-01-03
CU20140148A7 (es) 2015-03-30
US20200085958A1 (en) 2020-03-19
MX2014015902A (es) 2015-07-17
ZA201409291B (en) 2017-05-31
ES2938586T3 (es) 2023-04-12
CL2014003531A1 (es) 2015-08-28
AU2013282891A1 (en) 2015-01-22
EP2866837B1 (fr) 2022-12-14
CA2877083C (fr) 2020-10-06
JP6134788B2 (ja) 2017-05-24
US20190160171A1 (en) 2019-05-30
MX353280B (es) 2018-01-05
EA031522B1 (ru) 2019-01-31
IN2014DN11063A (fr) 2015-09-25
MA37809A1 (fr) 2017-07-31
CN104582733A (zh) 2015-04-29
AU2013282891B2 (en) 2018-04-12
HK1208374A1 (en) 2016-03-04
CN104582733B (zh) 2017-07-04
BR112014031773A2 (pt) 2017-06-27
JP2015522001A (ja) 2015-08-03
SG11201408658PA (en) 2015-02-27
US20150150987A1 (en) 2015-06-04
US20220354956A1 (en) 2022-11-10
UA113549C2 (xx) 2017-02-10
CR20140581A (es) 2015-02-06

Similar Documents

Publication Publication Date Title
CU24287B1 (es) Suministro de fármaco biodegradable para las composiciones hidrofóbicas
BR112013016662A2 (pt) composições biodegradáveis para administração de fármaco
HK1206268A1 (en) Non linear multiblock copolymer drug conjugates for the delivery of active agents
ECSP15013227A (es) Formulaciones acuosas estables de adalimumab
BR112015022674A2 (pt) inibidores de bromodomínio
EA201390662A1 (ru) Фармацевтическая композиция, содержащая дутастерид
BR112015018087A8 (pt) composto, composição farmacêutica e uso
EA201291372A1 (ru) Фармацевтическая композиция, содержащая дроспиренон, и набор для предупреждения зачатия
PH12015501096A1 (en) Composition for immediate and extended release
MD20150053A2 (ro) Produs de comicronizare cu conţinut de acetat de ulipristal
WO2012085284A3 (fr) Formulations pharmaceutiques à charge médicamenteuse élevée comprenant de la dronédarone et des sels pharmaceutiquement acceptables de celles-ci
EP4374861A3 (fr) Procédé de morcellement et/ou de ciblage de principes pharmaceutiquement actifs vers un tissu synovial
UA114469C2 (uk) Фармацевтична композиція, що містить протимікробний агент
EA201200249A1 (ru) Прасугрел в некристаллической форме и содержащая его фармацевтическая композиция
TR201803451T4 (tr) Olmesartan formülasyonlari.
TR200909785A1 (tr) Aktif ajan olarak sefdinir içeren farmasötik kompozisyonlar.
TN2011000352A1 (en) New combination of active ingredients containing a non steroidal anti inflammatory drug and a colchicoside derivative
TR201203084A2 (tr) Sefditoren pivoksil ve klavulanik asit içeren formülasyonlar.
TR201203083A2 (tr) Sefdinir ve klavulanik asit içeren farmasötik dozaj formu.
UA71540U (ru) Способ профилактики воспалительной реакции при хирургическом лечении осложненной увеальной катаракты